Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.21.2
Stockholders' Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 01, 2021
Jul. 22, 2016
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
May 24, 2021
Dec. 31, 2020
Dec. 04, 2020
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock, shares authorized     150,000,000 150,000,000     125,000,000    
Common stock par value (in dollars per share)     $ 0.0001 $ 0.0001     $ 0.0001    
Preferred stock, shares authorized     2,000,000 2,000,000     2,000,000    
Preferred stock, shares issued     250,000 250,000     250,000    
Aggregate value of shares subscribed     $ 37,000 $ 37,000     $ 7,939,000    
Common stock, shares issued     91,159,814 91,159,814     70,920,693    
Common stock, shares issuable     13,831 13,831     2,103,122    
Proceeds from issuance of common shares       $ 0 $ 37,230,000        
Aggregate fees of stock issuance       $ 0 $ 2,282,000        
Shares available for future sale     744,823 744,823          
Share-based compensation expense under ESPP     $ 400,000            
Proceeds from employee stock purchase plan       $ 300,000          
Fortress Biotech, Inc [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Percentage of fully diluted equity 2.50% 2.50%     2.50%        
Expenses from related party transaction       $ 375,000 $ 375,000        
Issuance of common shares (in shares)       517,304 117,405        
Shares issued, price per share     $ 3.84 $ 3.84 $ 3.56        
Common stock, shares issuable     52,019 52,019          
Proceeds from issuance of common shares         $ 66,900,000        
At the Market Offering [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Agent commission (as a percent)                 3.00%
Issuance of common shares (in shares)       17,300,000 7,200,000        
Shares issued, price per share     $ 3.87 $ 3.87 $ 3.56        
Proceeds from issuance of common shares       $ 66,900,000 $ 25,600,000        
Aggregate fees of stock issuance       1,300,000 $ 500,000        
Registration Statements [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Sale of Stock aggregate offering price permitted by agreement           $ 200,000,000.0   $ 100,000,000.0 $ 75,000,000.0
Common stock shares available for future issuance     $ 19,300,000 $ 19,300,000          
Class A Common Shares [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock, shares issued     845,385 845,385     845,385    
General and Administrative [Member] | Fortress Biotech, Inc [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Expenses from related party transaction       $ 1,700,000